Smith, N., & Blau, N. (2019). Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. Molecular genetics and metabolism, 126(4), . https://doi.org/10.1016/j.ymgme.2019.02.001
Chicago-Zitierstil (17. Ausg.)Smith, Neil, und Nenad Blau. "Phase I Clinical Evaluation of CNSA-001 (sepiapterin), a Novel Pharmacological Treatment for Phenylketonuria and Tetrahydrobiopterin Deficiencies, in Healthy Volunteers." Molecular Genetics and Metabolism 126, no. 4 (2019). https://doi.org/10.1016/j.ymgme.2019.02.001.
MLA-Zitierstil (9. Ausg.)Smith, Neil, und Nenad Blau. "Phase I Clinical Evaluation of CNSA-001 (sepiapterin), a Novel Pharmacological Treatment for Phenylketonuria and Tetrahydrobiopterin Deficiencies, in Healthy Volunteers." Molecular Genetics and Metabolism, vol. 126, no. 4, 2019, https://doi.org/10.1016/j.ymgme.2019.02.001.